Clark Jean, MD
Hematology & Oncology · Las Vegas, NVNPI 1205844750
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (59.1%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. It is spread thinly across 53 manufacturers, the largest accounting for just 21.9%. Reporting peaked in 2019 at $15,347 and has fallen 83.0% since, to $2,604 in 2025.
Across 397 payments — averaging $109.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$9K
- Johnson & Johnson$7K
- Bayer$7K
- Novocure Inc.$5K
- AstraZeneca$3K
- Gilead$2K
- plus $10K from 47 others
Across 25 payments — averaging $6703.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rigel Pharmaceuticals, Inc.$70K
- Astrazeneca UK Limited$68K
- AstraZeneca$25K
- Pfizer$5K
- Seagen Inc.$302
What the payments were for
- Consulting fees$25,61559%
- Speaking & faculty fees$5,66013%
- Travel & lodging$3,6458%
- Food & beverage$8,02619%
- Education$3751%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$43,321 in reported general payments places this provider in the 80th percentile of 82 hematology & oncology providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 99 | $1,494,747 |
| Lenalidomide | 81 | $969,299 |
| JakafiRuxolitinib Phosphate | 45 | $663,868 |
| ImbruvicaIbrutinib | 41 | $623,226 |
| PomalystPomalidomide | 28 | $573,207 |
| ErleadaApalutamide | 37 | $555,235 |
| CalquenceAcalabrutinib Maleate | 33 | $487,844 |
| BrukinsaZanubrutinib | 25 | $321,716 |
| KisqaliRibociclib Succinate | 18 | $310,681 |
| NubeqaDarolutamide | 17 | $213,559 |
| Abiraterone Acetate | 67 | $199,831 |
| EliquisApixaban | 187 | $156,383 |
| XareltoRivaroxaban | 101 | $95,487 |
| OctagamImmun Globg(Igg)/Malt/Iga Ov50 | 21 | $95,121 |
| Everolimus | 11 | $19,360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $1,934 | $1,494,74799 claims |
| Incyte CorporationJakafi | $109 | $663,86845 claims |
| Johnson & JohnsonErleada, Xarelto | $7,201 | $650,722138 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $107 | $623,22641 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $117 | $573,20728 claims |
| AstraZenecaCalquence | $2,647 | $487,84433 claims |
| Beigene USA, Inc.Brukinsa | $1,762 | $321,71625 claims |
| NovartisKisqali | $9,473 | $310,68118 claims |
| PfizerEliquis, Octagam | $653 | $251,504208 claims |
| BayerNubeqa | $6,515 | $213,55917 claims |
| Boehringer IngelheimPradaxa | $44 | $1,93011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 82 hematology & oncology providers in Nevada.
Other hematology & oncology in Las Vegas
- Nicholas VogelzangLas Vegas$397K
- Wolfram SamlowskiLas Vegas$235K
- Oscar GoodmanLas Vegas$211K
- Aaron GoodmanLas Vegas$134K
- Anuradha ThummalaLas Vegas$128K
- Ann WiermanLas Vegas$81K
- Heather AllenLas Vegas$78K
- Holavanahalli Keshava-PrasadLas Vegas$67K
- Edgardo FaylonaLas Vegas$53K
- Khawaja JahangirLas Vegas$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.